Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

om NASDAQ providing Peregrine with additional time to regain compliance with NASDAQ's $1.00 minimum bid price rule. Peregrine now has at least until October 26, 2009 to regain compliance.
  • Received shareholder approval at the Annual Meeting of Stockholders held on October 21, 2008, for a proposal that provides the company's Board of Directors with discretionary authority to implement a reverse split of the issued and outstanding shares of Peregrine's common stock before the 2009 Annual Meeting.
  • Conference Call

    The company will host a conference call today, July 14, 2009 at 11:30 a.m. EDT/8:30 a.m. PDT to discuss its fiscal year 2009 financial results.

    To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: www.peregrineinc.com. The webcast will be archived on Peregrine's website for approximately 30 days.

    To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through July 21, 2009 by calling (877) 344-7529, passcode 431883#.

    About Peregrine Pharmaceuticals

    Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, In
    '/>"/>

    SOURCE Peregrine Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine news :

    1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
    2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
    3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
    4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
    5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
    6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
    7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
    8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
    9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
    10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
    11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... new UCLA study has shown this is definitely the case ... how to treat their prostate cancer. , UCLA researchers found ... a much more difficult time making treatment decisions, called decisional ... their care and their long-term outcomes. , The study should ... the findings to target men less likely to know a ...
    (Date:8/27/2014)... Co-operative Research Centre into Microtechnologies, is coordinating ... innovative solutions based on microtechnologies to tackle ... life sciences, among others. IK4-Ikerlan, Ceit-IK4, IK4-Tekniker, ... with CIC microGUNE on this project, which ... Etortek 2013-2014 programme of the Government of ...
    (Date:8/27/2014)... 10 portions a week of tomatoes have an 18 ... research suggests. , With 35,000 new cases every year ... is the second most common cancer in men worldwide. ... experts believe is linked to a Westernised diet and ... recommendations reduces risk of prostate cancer, researchers at the ...
    (Date:8/27/2014)... This news release is available in German . ... need for medical agents to treat metastatic tumors. In case ... cancer that is often detected late, 95% of the patients ... amcure develops tumor therapeutic agents that might reduce this mortality ... has now received a total of EUR 5 million from ...
    (Date:8/27/2014)... CA (PRWEB) August 27, 2014 Bedros Keuilian ... franchise in the world, the leading fitness boot camp ... TV’s Gym Rescue reality series. One thing he knows very ... as a subject matter expert in the fitness business. , ... YouTube, he lays out a step-by-step instructional guide on how ...
    Breaking Medicine News(10 mins):Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Preclinical development of tumor therapeutic agent starts 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3
    ... National Kidney FoundationMOUNTAIN VIEW, Calif., April 20 Satellite ... of kidney dialysis services and a major sponsor of ... will be honored by the National Kidney Foundation at ... 23 at Yoshi,s Jazz Club in San Francisco. Linda ...
    ... 20 The managing director of Publication CONNEXION, ... speak at the 45th Annual Drug Information Association ... be present a talk entitled "Effective Publication Practices" ... is a pharmaceutical industry five-day summit uniting professionals ...
    ... San Diego just moved closer to unlocking the ... mode" to "specialization mode." This computational biology work ... could lead to new ideas for curbing unwanted ... Nature Genetics , could also improve our ...
    ... and Women,s Hospital (BWH) and the Harvard-MIT Division ... way to deliver cancer drugs directly to tumors by ... pathway and deliver a higher concentration of medication to ... April 20, in an early online edition of the ...
    ... - Federal stimulus package provides needed economic boost to ... April 20 House Speaker Nancy Pelosi joined ... and Family Health Center to discuss the positive impact ... communities, which granted more than $10 million in federal ...
    ... few signs, imaging reveals patients at much greater risk ... "Silent" heart attacks occur more often than previously believed ... death, according to a Duke University Medical Center study. ... myocardial infarctions (UMIs), often go undetected because they don,t ...
    Cached Medicine News:Health News:Renal Dietitian, Linda McCann, Receives 2009 Champion of Hope Award 2Health News:How cells change gears: New insights published in Nature Genetics 2Health News:How cells change gears: New insights published in Nature Genetics 3Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 2Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 3Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 4Health News:Speaker Pelosi Visits Florida Health Center 2Health News:'Silent' Heart Attacks More Common Than Thought 2
    (Date:8/27/2014)... --  Auxilium Pharmaceuticals , Inc. (NASDAQ: AUXL ... that certain members of the executive management team will ... held September 8-10, 2014 in New York ... and President, is scheduled to present an overview of ... ET on Wednesday, September 10, 2014. The ...
    (Date:8/27/2014)... PARK, Calif. , Aug. 27, 2014 ... the U.S. Food and Drug Administration (FDA) to initiate ... in patients with complete cervical spinal cord injury.  The ... 1 clinical study of the product, and is designed ... AST-OPC1 in patients with complete cervical spinal cord injuries, ...
    (Date:8/27/2014)... LONDON , Aug. 27, 2014 ... solutions, MarketResearch.com is pleased to announce the addition ... Devices Knowledge Center. The Medical Devices ... latest market research in the healthcare industry. Users ... from industry expert, Kalorama Information, published from 1998 ...
    Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 3
    ... ADA,s 2009 Convention -- When Shawnae Jebbia won the Miss ... fairytale career. She appeared at events throughout the world, worked ... Shawnae,s world unexpectedly changed when she was diagnosed with hearing ... she had a difficult time understanding and accepting the sudden ...
    ... Oct. 29 Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... , Sales in local currency declined by 12% in ... negative currency impact. , Net earnings per diluted ... third quarter of 2008. Adjusted EPS was $1.36, a 6% ...
    Cached Medicine Technology:Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 4Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 5Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 6Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 7Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 8Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 9Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 10Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 11Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 12Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 13
    A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
    ... The Laserex Tango ophthalmic laser system ... an SLT laser and a photodisruptor for ... is a frequency-doubled Nd:YAG producing pulsed 532 ... Nd:YAG producing 1064 nm. The appropriate laser ...
    ... is the unique combination laser system for ... of a button switch between SLT or ... Selecta Duet affords you the opportunity to ... the same setting with the benefits inherent ...
    Extremely thin and smooth jaws, jaws open to 5.5 mm, cross action....
    Medicine Products: